[MCOH-EH] Monkeypox exposure in HCWs

[Michael A. Sauri, MD, MPH&TM, FACP, FACPM]

Dr. Scott,

I serve as an Occupational Medicine consultant for several research
facilities who are currently working with orthopox viruses (including
Monkeypox).  For such non-highly attenuated vaccinia strains, we have been
giving workers ACAMBIS 2000 vaccination (via CDC).  My Staff and I are
up-to-date with our Vaccinia vaccination and have administered over 3000
smallpox vaccinations over three decades at Occupational Health Consultants
(OHC).   Compared to a every 10-year boosting cycle for researchers working
with non-highly attenuated vaccinia strains , a booster is recommended by
CDC every 3 years for anyone working with the more virulent orthopox viruses
(e.g. Monkeypox virus) .

 

I spoke with our CDC Vaccinia Vaccine contact earlier this month and CDC
plans to use Jynneos (replication-deficient modified vaccinia Ankara)
vaccine for "ring vaccination" strategy for high-risk close contacts of
monkeypox cases in the USA.   Jynneos is currently being used for "ring
vaccination" in the UK.  At that time, CDC had only 1000 doses of Jynneos
available. 

 

In addition to the ACAM2000 and Jynneos vaccines, TPOXX (Tecovirimat) and
Tembexa (brincidofovir, a lipid conjugate of cidofovir), alone or in
combination have been shown to be effective antiviral therapies for cases of
severe monkeypox in immunocompromised victims.  The US government has
stockpiled 1.7 million courses of Tecovirmat in the Strategic National
Stockpile.  Imvanex in Europe and Imvamune in Canada (makers of Jynneos) are
starting to gear up vaccine production in response to the monkeypox
outbreak.  

 

Depending on the number of Monkeypox cases in the USA, there may not be
enough Jynneos to give to researchers working with Monkey Pox virus until
the end of the year.  Consequently, we are continuing to offer ACAM2000 to
anyone who is planning to work with the Monkeypox virus.    Prior to
releasing any Jynneos vaccine, CDC is requesting that organizations  provide
them with a list of their healthcare workers who will be assigned to
treatment teams for a Monkey Pox victims, as well as, their researchers who
plan to work with Monkeypox virus.

 

I hope this is helpful.

Michael

 

Michael A. Sauri, MD, MPH&TM, FACP,

FACPM, FACOEM, FRSTM&H, CTropMed

Medical Director

Occupational Health Consultants

2301 Research Blvd, Suite 125

Rockville, MD 20850

Tel 301-738-6420

Fax 301-990-3534

msauri at ohcmd.com <mailto:msauri at ohcmd.com> 

 

From: MCOH-EH <mcoh-eh-bounces+msauri=ohcmd.com at mylist.net> On Behalf Of
William.Scott
Sent: Tuesday, June 28, 2022 12:45 PM
To: 'MCOH-EH' <mcoh-eh at mylist.net>
Subject: [MCOH-EH] Monkeypox exposure in HCWs

 

Looking for input of protocols for dealing with health care works exposer to
Monkeypox.

Our institution are interested in preparing for possible evaluation and care
of patients with rule out Monkeypox. 

Additionally I am interested in knowing if anyone in our group has look at
this from an employee exposure process.

Cheers. 

 

Bill

 

William Scott, MD, MPH, FACOEM

Clinical Associate Professor, Carle Illinois College of Medicine,

Clinical Assistant Professor, University of Illinois College of Medicine at
Urbana-Champaign 

Head, Occupational & Envionmental Medicine & Employee Health

Carle Foundation Hospital, Carle Physician Group. 

 

 



----
Secured by Paubox - HITRUST CSF certified
https://www.paubox.com
----
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <https://mylist.net/archives/mcoh-eh/attachments/20220628/b81603d3/attachment.htm>